Equillium (EQ) Income from Continuing Operations (2018 - 2026)
Equillium (EQ) reported Income from Continuing Operations of 5301000.0 for Q1 2026, up 39.05% year-over-year from 3812354.01 in Q1 2025, and down 134.71% quarter-over-quarter from 15271000.0 in Q4 2025.
Equillium (EQ) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Equillium (EQ) has 9 years of Income from Continuing Operations data on file, last reported at 5301000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 5301000.0, up 39.05% year-over-year; the trailing twelve-month figure through Mar 2026 was 476000.0 (up 96.61% YoY), and the FY2025 annual result was 22398000.0, down 177.65% from the prior year.
- Income from Continuing Operations eased to 5301000.0 in Q1 2026 per EQ's latest filing, from 15271000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 63176000.0 in Q4 2022 and troughed at 37417000.0 in Q1 2022.
- A 5-year average of 1916705.88 and a median of 3940000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations jumped 693.59% in 2022, then tumbled 61900.0% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 63176000.0 in 2022, then slumped by 103.68% to 2326000.0 in 2023, then plunged by 149.1% to 5794000.0 in 2024, then surged by 363.57% to 15271000.0 in 2025, then slumped by 134.71% to 5301000.0 in 2026.
- Business Quant data shows EQ's Income from Continuing Operations at 5301000.0 in Q1 2026, 15271000.0 in Q4 2025, and 4340000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | -5.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.30 Mn |
| Dec 31, 2025 | 15.27 Mn |
| Sep 30, 2025 | -4.34 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | -8.70 Mn |
| Dec 31, 2024 | -5.79 Mn |
| Sep 30, 2024 | -7,000.00 |
| Jun 30, 2024 | 468,000.00 |
| Mar 31, 2024 | -2.73 Mn |
| Dec 31, 2023 | -2.33 Mn |
| Sep 30, 2023 | -3.71 Mn |
| Jun 30, 2023 | -3.34 Mn |
| Mar 31, 2023 | -3.94 Mn |
| Dec 31, 2022 | 63.18 Mn |
| Sep 30, 2022 | -13.66 Mn |
| Jun 30, 2022 | -14.13 Mn |
| Mar 31, 2022 | -37.42 Mn |
| Dec 31, 2021 | -10.64 Mn |
| Sep 30, 2021 | -10.12 Mn |
| Jun 30, 2021 | -9.10 Mn |